Altium Capital Management LP purchased a new stake in Repro Med Systems, Inc. (NASDAQ:KRMD) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 728,487 shares of the company’s stock, valued at approximately $3,373,000. Altium Capital Management LP owned approximately 1.64% of Repro Med Systems at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in KRMD. BlackRock Inc. lifted its position in Repro Med Systems by 5.2% during the 1st quarter. BlackRock Inc. now owns 1,673,312 shares of the company’s stock worth $5,890,000 after buying an additional 82,562 shares in the last quarter. Geode Capital Management LLC grew its stake in Repro Med Systems by 20.7% in the 1st quarter. Geode Capital Management LLC now owns 452,946 shares of the company’s stock valued at $1,594,000 after buying an additional 77,775 shares during the last quarter. Renaissance Technologies LLC grew its stake in Repro Med Systems by 658.5% in the 1st quarter. Renaissance Technologies LLC now owns 152,800 shares of the company’s stock valued at $538,000 after buying an additional 132,656 shares during the last quarter. PEAK6 Investments LLC bought a new stake in Repro Med Systems in the 1st quarter valued at about $179,000. Finally, Alpha Paradigm Partners LLC boosted its holdings in Repro Med Systems by 4.8% in the 1st quarter. Alpha Paradigm Partners LLC now owns 62,473 shares of the company’s stock valued at $220,000 after purchasing an additional 2,860 shares during the period. 59.44% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have recently weighed in on KRMD shares. TheStreet downgraded shares of Repro Med Systems from a “c-” rating to a “d+” rating in a report on Tuesday, July 6th. Zacks Investment Research downgraded shares of Repro Med Systems from a “buy” rating to a “hold” rating in a report on Wednesday.
Repro Med Systems (NASDAQ:KRMD) last posted its quarterly earnings data on Wednesday, August 11th. The company reported ($0.02) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.02). The company had revenue of $5.53 million during the quarter, compared to analysts’ expectations of $5.01 million. Repro Med Systems had a negative net margin of 14.16% and a negative return on equity of 3.24%. On average, analysts anticipate that Repro Med Systems, Inc. will post -0.07 earnings per share for the current year.
In other Repro Med Systems news, Director Joseph M. Jr. Manko acquired 20,000 shares of the company’s stock in a transaction on Monday, August 16th. The shares were purchased at an average cost of $3.40 per share, with a total value of $68,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 35.00% of the stock is currently owned by company insiders.
About Repro Med Systems
Repro-Med Systems, Inc engages in the design, manufacture, and market of proprietary medical devices. Its product portfolio includes FREEDOM60, FreedomEdge syringe drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. The company was founded by Andrew I. Sealfon and Adrian W.
Featured Story: What economic reports are most valuable to investors?
Want to see what other hedge funds are holding KRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repro Med Systems, Inc. (NASDAQ:KRMD).
Receive News & Ratings for Repro Med Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repro Med Systems and related companies with MarketBeat.com's FREE daily email newsletter.